Trial Profile
A Randomized, Placebo-controlled, Single-blind Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of Otelixizumab in Rheumatoid Arthritis Subjects.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 02 Oct 2023
Price :
$35
*
At a glance
- Drugs Otelixizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK
- 15 Nov 2013 Status changed from active, no longer recruiting to discontinued a sreported by ClinicalTrials.gov.
- 12 Apr 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 14 Nov 2011 Trial phase changed from II to I as reported by ClinicalTrials.gov.